Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828075 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TSHRACHETDP1CA2 | |
| SCHEMBL3615102 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TSHRACHETDP1MAPT | |
| SCHEMBL12749948 | 0.73 | PTPN5 (0.38) | ALDH1A1 | |
| SCHEMBL728216 | 0.72 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1CA2MAPT | |
| SCHEMBL132308 | 0.72 | ALDH1A1 (0.46) | ALDH1A1TSHRACHETDP1CA2 | |
| SCHEMBL2137923 | 0.72 | ALDH1A1 (0.46) | ALDH1A1TSHRACHETDP1CA2 | |
| SCHEMBL816352 | 0.72 | ACHE (0.46) | ALDH1A1ACHETDP1MAPTCYP2C19 | |
| SCHEMBL9999807 | 0.69 | TSHR (0.42) | ALDH1A1TSHRACHECA2CA1 | |
| SCHEMBL19356905 | 0.68 | — | — | |
| SCHEMBL16982395 | 0.67 | ALDH1A1 (0.61) | ALDH1A1TSHRACHETDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-8067625-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8049022-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-01 | — | — | US | disclosed |
| US-7834004-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100152081-A1 | Fluorosurfactants | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20090312432-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090264525-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7517884-B2 | {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes | KALYPSYS INC. (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312432-A1 | FLUOROSURFACTANTS | SGMS2, FASN, SGMS1 | ALDH1A1 2479/4885TSHR 1160/4885ACHE 4091/4885 |
| US-20100152081-A1 | Fluorosurfactants | CBR3, FPR3, NOX3 | ALDH1A1 2466/4885TSHR 886/4885ACHE 3673/4885 |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | ALDH1A1 1551/4885TSHR 262/4885ACHE 2442/4885 |
| US-20090264525-A1 | FLUOROSURFACTANTS | FASN, FFAR3, SGMS2 | ALDH1A1 2925/4885TSHR 754/4885ACHE 4537/4885 |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | ALDH1A1 1551/4885TSHR 262/4885ACHE 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.